Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm D Mason

Showing results (101-110 of 146) with videos related to

Pageof 15
Sort By:
European Urology Oncology|June 28, 2020
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison"Adnan Ali, Alex P Hoyle, Christopher C Parker, et al.
BMC Cancer|October 17, 2019
Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes studyDavid W Donnelly, Linda C Vis, Therese Kearney, et al.
European Urology|September 5, 2016
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerPhilip Cornford, Joaquim Bellmunt, Michel Bolla, et al.
The Lancet. Oncology|January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataClaire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
European Urology|January 27, 2018
Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018Henk G van der Poel, Roderick C N van den Bergh, Erik Briers, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2017
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysisLarysa H M Rydzewska, Sarah Burdett, Claire L Vale, et al.
JAMA Oncology|February 18, 2021
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAdnan Ali, Alex Hoyle, Áine M Haran, et al.
Trials|September 18, 2012
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trialMatthew R Sydes, Mahesh K B Parmar, Malcolm D Mason, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Pageof 15

Showing results (101-110 of 146) with videos related to

Sort By:
Pageof 15
European Urology Oncology|June 28, 2020
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison"Adnan Ali, Alex P Hoyle, Christopher C Parker, et al.
BMC Cancer|October 17, 2019
Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes studyDavid W Donnelly, Linda C Vis, Therese Kearney, et al.
European Urology|September 5, 2016
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerPhilip Cornford, Joaquim Bellmunt, Michel Bolla, et al.
The Lancet. Oncology|January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataClaire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
European Urology|January 27, 2018
Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018Henk G van der Poel, Roderick C N van den Bergh, Erik Briers, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2017
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysisLarysa H M Rydzewska, Sarah Burdett, Claire L Vale, et al.
JAMA Oncology|February 18, 2021
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAdnan Ali, Alex Hoyle, Áine M Haran, et al.
Trials|September 18, 2012
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trialMatthew R Sydes, Mahesh K B Parmar, Malcolm D Mason, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Pageof 15